• Seres Therapeutics published Phase 1b results for SER-155 in Nature Medicine on Nov. 3, 2026.
• SER-155 reduced bloodstream infections and systemic antibiotic exposure versus placebo in adults undergoing allogeneic hematopoietic cell transplantation.
• The investigational treatment was generally well tolerated, with no treatment-related serious adverse events observed.
• SER-155 holds FDA Breakthrough Therapy designation; its planned Phase 2 transplant study is ready to start pending funding.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seres Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030700PRIMZONEFULLFEED9868992) on November 03, 2026, and is solely responsible for the information contained therein.